PDF(33604 KB)
阿替利珠单抗的专利布局及分析
赵天, 李自财, 黄璐,
PDF(33604 KB)
PDF(33604 KB)
阿替利珠单抗的专利布局及分析
Patent Layout and Analysis of Atezolizumab
阿替利珠单抗 / PD-L1 抑制剂 / 肿瘤免疫治疗 / 专利技术分析 / 专利布局 {{custom_keyword}} /
atezolizumab / PD-L1 inhibitor / tumor immunotherapy / patent technology analysis / patent layout {{custom_keyword}} /
[1] HODI F S, O’DAY S J, MCDERMOTT D F, et al．Improved survival with ipilimumab in patients with metastatic melanoma [J]．N Engl J Med, 2010, 363(8): 711-723．
[2] RIBAS A, WOLCHOK J D．Cancer immunotherapy using checkpoint blockade [J]．Science, 2018, 359(6382): 1350- 1355．
[3] YI M, ZHENG X, NIU M, et al．Combination strategies with PD-1/PD-L1 blockade: current advances and future directions [J]．Mol Cancer, 2022, 21(1): 28．
[4] GONG J, LE T Q, MASSARELLI E, et al． Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination [J]．J Immunother Cancer, 2018, 6(1): 46．
[5] FDA．Atezolizumab for urothelial carcinoma [EB/OL]． (2016-05-19) [2024-03-01]．https://www．fda．gov/ drugs/resources-information-approved-drugs/atezolizumaburothelial- carcinoma．
[6] INMAN B A, LONGO T A, RAMALINGAM S, et al． Atezolizumab: a PD-L1-blocking antibody for bladder cancer [J]．Clin Cancer Res, 2017, 23(8): 1886-1890．
[7] HERBST R S, GIACCONE G, DE MARINIS F, et al． Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC [J]．N Engl J Med, 2020, 383(14): 1328-1339．
[8] SCHMID P, ADAMS S, RUGO H S, et al．Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer [J]． N Engl J Med, 2018, 379(22): 2108-2121．
[9] MITTENDORF E A, ZHANG H, BARRIOS C H, et al． Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer(IMpassion031): a randomised, double-blind, phase 3 trial [J]．Lancet, 2020, 396(10257): 1090-1100．
[10] LEE M S, RYOO B Y, HSU C H, et al．Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study [J]． Lancet Oncol, 2020, 21(6): 808-820．
[11] 刘 建, 黄 璐．中国医药企业知识产权管理[M]．北京: 知识产权出版社, 2021．
[12] 葛 凡, 孙 建, 黄 璐．小分子周期蛋白依赖性激酶4/6 抑制剂药物及其专利研究[J]．中国医药工业杂志, 2022, 53(4): 464-473． [13] 黄 璐, 钱丽娜, 张晓瑜, 等．医药领域的专利保护与专 利布局策略[J]．中国新药杂志, 2017, 26(2): 139-144．
/
| 〈 |
|
〉 |
